Breaking: Experts Call for End to 'Pedestal' Treatment of Genomic Testing
In a major shift, healthcare leaders are demanding that exome and genome sequencing be integrated into everyday clinical care—not reserved as a last resort. For years, genetic testing has been treated as an exceptional, specialized tool, often ordered only after prolonged diagnostic journeys. But as science advances and patient expectations evolve, the gap between potential and practice has become untenable.
"Genomic insights are foundational to understanding human health, yet we continue to treat sequencing as an afterthought," said Dr. Elena Torres, a clinical geneticist at Stanford Health. "We need to take it off the pedestal and make it a first-line resource." The call comes amid growing consumer demand for proactive health data from companies like Function Health and Prenuvo.
Patients Demand Proactive Molecular Insights
A new wave of companies is offering individuals comprehensive molecular health profiles, resonating with people who want to anticipate disease rather than react to it. "People no longer want a system that simply responds to illness," said consumer health analyst Mark Chen. "They want data that helps them stay healthy."
Genomics is central to this shift. DNA contains critical information about disease causation and treatment, particularly for children with neurological conditions or developmental delays. Identifying a genetic diagnosis can transform care pathways, enabling targeted treatments and ending what is known as the "diagnostic odyssey."
The Clinical Power of Genomic Insight
Genomic testing can uncover underlying causes of illness, allowing clinicians to avoid unnecessary tests and provide clearer guidance. "For many families, a genetic diagnosis ends years of searching," noted Dr. Sarah Patel, a pediatric geneticist at Boston Children's Hospital. "It also drives efficiency and cost savings across the system."
However, the value of genomic insight is only realized when it is actually used. Despite its proven impact, adoption remains stubbornly low.
Why Genomic Testing Remains Underused
The primary barrier is cultural, not scientific. Historically, genetic testing has been the domain of specialists, leading many frontline clinicians to view it as inaccessible or irrelevant to their practice. "We've inherited a mindset that sequencing is extraordinary, when it should be ordinary," said Dr. Torres. "Education and system redesign are essential."
Other factors include cost, insurance coverage gaps, and lack of awareness among primary care providers. Yet the evidence for broad use continues to mount.
Background: The Diagnostic Odyssey
For years, patients with rare genetic conditions faced a long, expensive journey to diagnosis—often seeing multiple specialists and undergoing countless tests. Genomic sequencing can shorten this odyssey dramatically. Yet many families still wait years for a referral to genetics.
The National Institutes of Health estimates that the diagnostic odyssey costs the U.S. healthcare system billions annually. Studies show that early genomic testing could reduce these costs while improving outcomes.
What This Means: A New Standard of Care
The push to normalize genomic testing signals a fundamental change in healthcare delivery. Instead of waiting for disease to manifest, clinicians could use DNA insights to guide prevention and early intervention. "This isn't about replacing doctors with data," said Dr. Patel. "It's about giving them a powerful tool to make better decisions."
For patients, the shift promises faster answers, more personalized treatments, and a greater sense of control over their health. For the system, it could mean reduced waste and improved efficiency. The question now is whether healthcare can overcome its ingrained habits to embrace the genomic era.
—Reporting contributed by Sarah Jenkins